Phaos Technology Holdings (Cayman) (POAS) Cash & Equivalents (2024 - 2025)
Phaos Technology Holdings (Cayman) (POAS) reported Cash & Equivalents of $54989.0 for Q4 2025, down 43.26% quarter-over-quarter from $96918.3 in Q2 2025.
Phaos Technology Holdings (Cayman) (POAS) Cash & Equivalents (2024 - 2025) Analysis & Trends
Phaos Technology Holdings (Cayman) has reported Cash & Equivalents for 2 years, with the latest figure at $54989.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents changed N/A year-over-year to $54989.0; the trailing twelve-month figure through Oct 2025 stood at $54989.0 (changed N/A YoY), and the FY2025 full-year result was $97007.0, down 94.35% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $54989.0, down from $96918.3 in the prior quarter.
- The five-year high for Cash & Equivalents was $1.7 million in Q2 2024, with the low at $54989.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 6.80 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 2.45 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 2.29 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 3.03 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 1.12 Bn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 439.60 Mn |
| 10 | Phaos Technology Holdings (Cayman) | 575,783.30 | 520,794.30 | - | 54,989.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 54,989.00 |
| Apr 30, 2025 | 96,918.26 |
| Apr 30, 2024 | 1.72 Mn |